Pages that link to "Q85232838"
Jump to navigation
Jump to search
The following pages link to An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study (Q85232838):
Displaying 4 items.
- Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer. (Q53614521) (← links)
- Prostate cancer: Bicalutamide dose increase in castration-resistant disease (Q86208819) (← links)
- Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide (Q90169010) (← links)
- Switching from a gonadotropin-releasing hormone (GnRH) agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis (Q92203321) (← links)